(Q37868923)

24 August 2017

1 reference

title

The role of immunity in Huntington's disease (English)

1 reference

24 August 2017

0 references

D Soulet

1

1 reference

24 August 2017

F Cicchetti

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

26 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

16

1 reference

24 August 2017

889-902

1 reference

24 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/mp.2011.28

24 August 2017

0 references

cites work

Beyond the brain: widespread pathology in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Established and emerging therapies for Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

The current clinical management of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Advances in the Pharmacological Management of Huntingtonʼs Disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Mechanisms of neurodegeneration in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

https://api.crossref.org/works/10.1038%2FMP.2011.28

1 reference

7 January 2021

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Neuropathological classification of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Early and progressive accumulation of reactive microglia in the Huntington disease brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Imaging microglial activation in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Neuroinflammation in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Neuroendocrine disturbances in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Formation of polyglutamine inclusions in non-CNS tissue

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Targeting glial cells to elucidate the pathogenesis of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Glutamate uptake is reduced in prefrontal cortex in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Microglia in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Invited Article: Nervous system pathology in sporadic Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Brain targeting through the autonomous nervous system: lessons from prion diseases

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Parkinson's disease: a dual-hit hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Immunological features of alpha-synuclein in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Investigation into the role of macrophages in the formation and degradation of beta2-microglobulin amyloid fibrils

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

The proteasome: a central regulator of inflammation and macrophage function

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Neuronal and glial cell biology

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Lack of minocycline efficiency in genetic models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline in phenotypic models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline for Huntington's disease: an open label study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Neuroprotection in Huntington's disease: a 2-year study on minocycline

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline in Huntington's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Revisiting safety of minocycline as neuroprotection in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline and neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Mouse models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Trinucleotide repeat length instability and age of onset in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Huntington's disease: the current state of research with peripheral tissues.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Bone-marrow-derived microglia: myth or reality?

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Harnessing immune alterations in neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Microglial activation in presymptomatic Huntington's disease gene carriers

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.28

7 January 2021

Identifiers

DOI

10.1038/MP.2011.28

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference